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Received February 21, 2014; accepted April 12, 2014AbstractBackground: We developed an artificial neural network (ANN) model to predict prostate cancer pathological staging in patients prior to when
they received radical prostatectomy as this is more effective than logistic regression (LR), or combined use of age, prostate-specific antigen
(PSA), body mass index (BMI), digital rectal examination (DRE), trans-rectal ultrasound (TRUS), biopsy Gleason sum, and primary biopsy
Gleason grade.
Methods: Our study evaluated 299 patients undergoing retro-pubic radical prostatectomy or robotic-assisted laparoscopic radical prostatectomy
surgical procedures with pelvic lymph node dissection. The results were intended to predict the pathological stage of prostate cancer (T2 or T3)
after radical surgery. The predictive ability of ANN was compared with LR and validation of the 2007 Partin Tables was estimated by the areas
under the receiving operating characteristic curve (AUCs).
Results: Of the 299 patients we evaluated, 109 (36.45%) displayed prostate cancer with extra-capsular extension (ECE), and 190 (63.55%)
displayed organ-confined disease (OCD). LR analysis showed that only PSA and BMI were statistically significant predictors of prostate cancer
with capsule invasion. Overall, ANN outperformed LR significantly (0.795 ± 0.023 versus 0.746 ± 0.025, p ¼ 0.016). Validation using the
current Partin Tables for the participants of our study was assessed, and the predictive capacity of AUC for OCD was 0.695.
Conclusion: ANN was superior to LR at predicting OCD in prostate cancer. Compared with the validation of current Partin Tables for the
Taiwanese population, the ANN model resulted in larger AUCs and more accurate prediction of the pathologic stage of prostate cancer.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Radical prostatectomy (RP) is the most effective therapy
for adeno-carcinoma of the prostate when the cancer is either
organ- or specimen-confined at the time of operation.1e3
Therefore, it is beneficial for patients with prostate cancer
and their physicians to be able to predict the pathologic stage
of the disease before surgery. In 1997, Partin et al4 used aociation. All rights reserved.
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analysis, clinical classification, and the Gleason score to pre-
dict the pathologic stage of localized prostate cancer in a
multi-institutional study. However, the predictive values of the
current Partin Tables, which were updated in 20015 and 2007,6
have not been validated in most Asian populations, including
Taiwan.
We developed the artificial neural network (ANN) using
readily available clinical data to improve the prediction of
prostate cancer staging compared with currently available
staging methods. ANN is a computer modeling approach
based loosely on the function of a biological neuron and its
relationship to a neural network. In this study, we performed a
cross-sectional investigation to develop ANN for predicting
the final pathologic stage of prostate cancer in patients who
had undergone RP. The results were compared with two other
predictive models: a logistic regression (LR) model and the
2007 Partin Tables. To our knowledge, this is the first study to
use an ANN model to predict the pathologic stage of prostate
cancer in a Taiwanese population, which also allows a com-
parison with the existing LR method and to further validate the
current Partin Tables.
2. Methods
In this study, we used pathologic and clinical data taken at
the time of prostate biopsies to develop and test an ANN model
for predicting the final pathologic stage of disease. Then, we
compared ANN with two other modeling techniques, where one
model employed multivariate LR and the other the Partin Ta-
bles, as described in previous studies. Patients enrolled in the
study had all undergone an RP surgical procedure at Tri-Service
General Hospital, Taipei, Taiwan from September 2001 to April
2012. The final cohort study, consisting of 299 patients, was
randomly divided into two mutually exclusive datasets: the
training set and testing set. Written informed consent was ob-
tained from all patients and the study protocol was approved by
the appropriate ethics committees.
Discussions with several urologists revealed which vari-
ables they believed were most significant in determining the
pathologic result of prostate cancer after the radical prosta-
tectomy procedure. The resulting list of seven variables
included PSA expression, age, body mass index (BMI), digital
rectal examination (DRE), trans-rectal ultrasound (TRUS),
biopsy Gleason sum, and primary biopsy Gleason grade.
Among these variables, only DRE and TRUS were categorical
classifications. The positive findings of DRE and TRUS were
defined as a palpable hard nodule assessed via the digital rectal
examination and a hypoechogenic lesion via the trans-rectal
ultrasound image. The final report was dependent upon
whether the capsule invasion of the prostate cancer was
detected in the pathological specimen [organ-confined disease
(OCD) or with extra-capsular extension (ECE)].
In this study, ANNs were generated using the software
package STATISTICA Neural Networks (Release 7.0 E) from
StatSoft Inc. Various formulations were used to train and
predict the likelihood of capsule invasion of prostate cancerafter radical prostatectomy from the seven independently
predictive variables mentioned above. Different network ar-
chitectures tested included linear networks, multilayer per-
ceptrons, and radial basis function networks.
The dataset was randomly divided into two separate groups:
225 patients (~75%) as the training set and 74 patients (~25%)
as the testing set. As no well-established theoretical method
exists for designing an ideal ANN, and the optimal number of
hidden nodes and iterations are unknown, the best designs are
typically determined through trial and error. All models were
evaluated with the testing set to determine their accuracy in
predicting patients that require RP procedures.
A multivariate LR model was developed using SPSS
version 13.0 (SPSS Inc., Chicago, IL, USA). All of the vari-
ables were unconditionally entered into the LR equation as
they were already deemed significant in the second step of the
variable selection process. The predictor variables were: (1)
total serum PSA levels prior to radical surgery, which were
categorically divided into 0e2.5 ng/mL, 2.6e4.0 ng/mL,
4.1e6.0 ng/mL, 6.1e10 ng/mL, and >10 ng/mL; (2) TNM
clinical stage,7 which was categorically divided into T1c, T2a,
T2b, or T2c; and (3) biopsy Gleason score sum, which was
divided categorically into 2e4, 5e6, 3 þ 4 ¼ 7, 4 þ 3 ¼ 7,
and 8e10. We validated our cases against the current Partin
Tables6 to predict the final pathological stage (OCD or ECE).
According to a detailed overview of each of the probability
intervals (1%, 2%, etc. up to 99%), we obtained different
predicted results plotted as a receiver operating characteristic
(ROC) curve.
The result of the LR and ANN predictive models on a per
patient basis was plotted as ROC curves. The area under the
ROC curves (AUCs) with a 95% confidence interval (CI) was
used as a quantitative measure of the ability of the predictor
models to distinguish between responders and non-responders.
3. Results
For the 299 participants, the mean age was 66.11 ± 7.61
years (range 49e78 years), the mean baseline BMI was
24.86 ± 3.71 kg/m2, the mean PSA expression was
16.26 ± 17.88 ng/mL, the mean biopsy Gleason sum was
6.82 ± 1.22, and the primary biopsy Gleason grade was
3.37 ± 0.69. Of the participants, 109 (36.45%) displayed
prostate cancer with ECE and 190 (63.55%) showed OCD.
Among the ECE and OCD groups, positive DRE rates were
30.3% and 15.8%, respectively, and positive TRUS ratios were
33.0% and 18.9%, respectively. Except for the age factor, the
independent variables including BMI, PSA, biopsy Gleason
sum, primary biopsy Gleason grade, positive rate of DRE, and
TRUS were statistically significantly higher in the ECE than in
the OCD groups (Table 1). From the results of initial ANN
analyses, we found that the standard feed-forward, fully-con-
nected, back-propagation neural network with 16 hidden
nodes provided the optimal network architecture.
In this model, the hyperbolic and logistic functions were
used as an activation function in the hidden and output layers,
respectively. Most continuous variables including BMI, PSA,
Table 1
Comparison of a range of parameters between prostate cancer (PC) with extra-







Age 66.65 ± 7.56 65.79 ± 7.65 0.350
BMI 25.71 ± 4.87 24.37 ± 2.74 0.002
PSA 23.45 ± 22.20 12.13 ± 13.24 <0.001
Biopsy Gleason sum 7.22 ± 1.38 6.59 ± 1.06 <0.001
Primary biopsy Gleason grade 3.58 ± 0.76 3.26 ± 0.62 <0.001
Categorical variables
DRE (þ) 33 (30.3) 30 (15.8) 0.005
TRUS (þ) 36 (33.0) 36 (18.9) 0.009
Data are presented as n (%) or mean ± SD.
BMI ¼ body mass index; DRE ¼ digital rectal examination; OCD ¼ organ-
confined disease; PC ¼ prostate cancer; PSA ¼ prostate-specific antigen;
TRUS ¼ trans-rectal ultrasound.
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shown to be statistically significant when applying the uni-
variate logistic regression model ( p ¼ 0.005, p < 0.005,
p < 0.001, p < 0.001). The categorical variables including
DRE and TRUS also showed statistically influence on the final
pathologic report with OCD or ECE ( p ¼ 0.004, p ¼ 0 .007).
When multivariate logistic regressions were analyzed after
adjusting other risk factors, only PSA ( p ¼ 0.001) and BMI
( p ¼ 0.023) had a statistical role in the prediction of the final
prostate cancer pathological stage (Table 2). The classification
threshold for the predicted values was optimally set to 0.491.
The entropy function was used to estimate the error. From our
statistical result, the overall accuracy rate of the ANN was
65%, which was higher than LR at 60% and magnetic reso-
nance imaging (MRI) at 61%. The sensitivity rates for ANN,
LR, and MRI prediction were 83%, 70%, and 43%, respec-
tively, and the specific rates were 56%, 56%, and 73%,
respectively (data not shown). In other words, our study results
show that the clinical image tool for prostate cancer staging,
MRI, revealed poorer predictive ability than previous ANN
and LR models.
Using the AUCs as a measure of predictive model perfor-
mance, overall ANN outperformed LR to a statistically
significantly extent (0.795 ± 0.023 versus 0.746 ± 0.025,Table 2
Univariate and multivariate logistic regression (LR) analyses for prediction of






Age 1.02 (0.98e1.05) 0.349 1.01 (0.97e1.04) 0.645
BMI 1.13 (1.04e1.22) 0.005 1.10 (1.01e1.0) 0.023
PSA 1.05 (1.03e1.07) <0.001 1.03 (1.02e1.05) 0.001
Biopsy Gleason
sum
1.57 (1.27e1.94) <0.001 1.22 (0.86e1.73) 0.257
Primary Gleason
grade
2.00 (1.39e2.86) <0.001 1.17 (0.64e2.14) 0.610
DRE (P vs N) 2.32 (1.32e4.00) 0.004 1.39 (0.61e3.13) 0.438
TRUS (P vs N) 2.13 (1.23e3.57) 0.007 1.28 (0.59e2.78) 0.528
BMI ¼ body mass index; DRE ¼ digital rectal examination; PSA ¼ prostate-
specific antigen; TRUS ¼ trans-rectal ultrasound.p ¼ 0.016; Fig. 1A). The internal validation of ANN in testing
patients also showed better performance than the LR predic-
tive model (0.735 ± 0.051 versus 0.65 ± 0.055, p ¼ 0.093,
Fig. 1B). We next performed validation of the current Partin
Tables6 using the data collected from Taiwanese patients at a
single center, according to clinical stage, PSA expression
levels, and Gleason score sum. We analyzed the sensitivity and
specificity rates according to previously mentioned forward
order categorical probabilities (1%, 2%, etc. up to 99%, 100%)
for all the patients, then applied the Partin Table model and an
AUC of 0.695 was obtained (Fig. 2). Validation of this clini-
cally applied model revealed a poorer predictive capacity
compared with the ANN and LR models.
4. Discussion
Oesterling et al1 initially attempted to predict the patho-
logic stage of clinically localized prostate cancer using LR. In
1993, Partin et al2 developed an LR-based nomogram for
predicting the final pathologic stage. They combined the PSA
expression level, clinical classification, and the Gleason scoreFig. 1. (A) The predictive model of ANN overall outperformed LR overall
significantly (0.795 ± 0.023 versus 0.746 ± 0.025; p ¼ 0.016, n ¼ 299). (B)
The predictive ability of ANN testing outperformed LR testing (0.735 ± 0.051
versus 0.65 ± 0.055; p ¼ 0.093, n ¼ 74). ANN ¼ artificial neural network;
LR ¼ logistic regression.
Probability 
(%) 







Sensitivity 0.128 0.266 0.551 0.679 0.743 0.752 0.853 0.945 1 
1-specificity 0.005 0.058 0.259 0.355 0.423 0.534 0.714 0.899 0.974 
Fig. 2. The study of 299 cases validated the clinical Partin Tables and the
predictive ability of AUC showed 0.695. AUC ¼ areas under the receiving
operating characteristic curve; ROC ¼ receiver operating characteristic.
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localized prostate cancer by a single surgeon at Johns Hopkins
Hospital (Baltimore, MD, USA). Partin et al5,6 subsequently
combined the clinical data from three academic institutions
and updated the LR-based nomogram to simultaneously pre-
dict the pathological stage.
ANNs and logistic regression have become two of the
fastest growing and most effective systems in prostate cancer
diagnosis. ANN is also an adaptive computational model
designed to mimic the interconnected neurons of the brain,
whose properties change when external or internal information
flows through the network.8 ANNs belong to the back-
propagation class of neural networks in which models use
training methods to minimize errors. ANNs are normally
divided into three parts: input, hidden, and output layers of
neurons whereby the inputs of each neuron are “weighted” by
certain coefficients. Rosenblatt9 first used ANNs in clinical
radiology in 1958, and its use in urologic decision making was
first described by Snow et al.10
In 1998, Tewari and Narayan11 developed ANN models for
pretreatment staging of prostate adenocarcinoma in 1200
males for the detection of ECE in patients with clinical OCD.
Input variables included age, race, rectal examination findings,
size of gland using ultrasound, serum PSA levels, systemic
biopsy-based staging information, perineural infiltration data,
and Gleason score from biopsy. In a side-by-side comparison,Borque et al12 found a greater AUC for ANN than for a lo-
gistic regression model for predicting extraprostatic disease in
a population of >400 males, although this result was not sta-
tistical significance ( p ¼ 0.1). Veltri et al13 similarly found
only a marginal advantage (~5%) for their ANN compared
with a logistic regression model with regard to staging accu-
racy using several biopsy parameters including a number of
positive cores, Gleason score sum, presence of Gleason Grade
4 or 5 tissue, total percentage of tumor involvement, and
average percentage of tumor involvement per core as well as
positive core and tumor location. A further study by Mattfeldt
et al14 also estimated the postoperative pathological stage of
prostate cancer using ANN with preoperative parameters,
which included age, histopathological variable, and prostate
volume. Different ANN models could correctly predict path-
ological stages pT3a in 90% of newly presented cases.
However, the results of the above study were obtained from a
small sample population (n ¼ 97) in which case the method-
ology needs to be validated using a large cohort. Finally, one
research group predicted pathological stage using seven pa-
rameters (age, PSA, clinical TNM classification, Gleason
score, the percentage of tumor-positive biopsy cores, the
maximum tumor length in biopsy cores, and PSA density).15
The AUC of the ANN (0.825) was greater than for the lo-
gistic regression model (0.782) but was not statistical signifi-
cant ( p ¼ 0.69). Recently, ANNs have helped clinics to
discriminate the detection of prostate cancer in the daily
routine and reduce unnecessary biopsies.16
The multivariate analysis of the logistic regression showed
that not only PSA but also BMI took an independent risk
factor for the prediction of the prostate cancer pathologic
stage. Recent studies17e19 have focused on the impact of
obesity associated with prostate cancer progression, aggres-
siveness as well as clinically worse outcomes. Although
obesity was not included in the parameters of previous referent
ANN predictive models of prostate cancer, we nevertheless
stressed its importance for the predictive accuracy of our
model for differentiating ECE or OCD. Therefore, we added
the obesity factor, assessed using the BMI value in the ANN
and LR models, for predicting the prostate cancer pathologic
stage.
Yoon et al20 went as far as developing a Korean-based
predictive model, which is a Korean Prostate Cancer Risk
Calculator (KPCRC) to predict prostate cancer detection. The
KPCRC improves the performance of the Prostate Risk
Calculator 3 (PRC 3; a Dutch-based design) and PSA testing
in predicting a Korean population's risk of prostate cancer. It
implies that Asian populations require their own risk calcu-
lators to more accurately assess staging for prostate cancer.
Bhojani et al21 reported that the Partin Tables were not ac-
curate enough to influence pre-operative decision making
regarding the type or extent of RP. Although nomograms or
Partin Tables have been developed and generally applied in
Western populations, extrapolation of these results to oriental
males may be of limited usefulness or validity.4 Because
serum PSA levels in Asian males are generally lower than
those of Caucasian males of the same age, the clinical
517C.-W. Tsao et al. / Journal of the Chinese Medical Association 77 (2014) 513e518significance of a given serum PSA value may differ between
the two populations.22 The appropriateness of the clinical
application of Partin Tables in Asian populations to predict the
pathologic stage of prostate cancer is therefore in doubt.
Although the previous study of Matsui et al15 validated the
Partin Tables in a Japanese population, it had a weaker but not
significant predictive ability than their ANN model,
( p ¼ 0.54). Nevertheless, this, to our knowledge, is the first
clinical validation study of the Partin Tables in a Taiwanese
population. Compared with the study reported by Poulakis
et al23 the ANN model incorporating MRI findings was
significantly more accurate than LR and the Partin Tables for
predicting the pathological stage of prostate cancer. As for our
ANN model, when MRI findings were included in the input
variables, the performance of the ANN showed a lower AUC
and poorer discrimination power (data not presented). There-
fore, MRI findings were omitted from the input variables of
the final ANN model.
The limitations of our study include relatively small sample
sizes, and the predictive accuracy of our model could poten-
tially have been increased by incorporating new biomarkers.
Kallikrein-224 and kallikrein-11 levels25 were reported to
improve the sensitivity and specificity of prostate cancer
detection. Salami et al26 stated that combining serum PSA,
PCA3, and TMPRSS2:ERG in a multivariable algorithm
optimized for clinical utility improved prostate cancer pre-
diction. Other gene markers like prostate-specific membrane
antigen, prostate stem cell antigen, apoptosis related mole-
cules, and cell-cycle-related biomarkers could be designed and
integrated into the ANN predictive model.27 In the future,
multi-center or multi-institute studies may therefore offer
more insight into the optimization of the ANN model.
Furthermore, other models, such as the NeuroeFuzzy model,
could be applied for more accurate clinical diagnoses.
In conclusion, the ANN model proved to be more accurate
and had a larger AUC than LR, and validated the Partin Tables
in predicting prostate cancer with OCD or ECE. ANNs can
therefore be used to assist patients with newly diagnosed
prostate cancer by helping to make more informed treatment
decisions.
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